Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation

被引：54

作者：

Jurisic, Vladimir ^{[1
]}

Obradovic, Jasmina ^{[2
]}

Pavlovic, Sonja ^{[3
]}

Djordjevic, Natasa ^{[1
]}

机构：

[1] Univ Kragujevac, Fac Med Sci, Svetozara Markovica 69, Kragujevac 34000, Serbia

[2] Univ Kragujevac, Fac Sci, Inst Biol & Ecol, Radoja Domanovica 12, Kragujevac 34000, Serbia

[3] Univ Belgrade, Inst Mol Genet & Genet Engn, Vojvode Stepe 444a, Belgrade 11010, Serbia

来源：

ANALYTICAL CELLULAR PATHOLOGY | 2018年 / 2018卷

关键词：

GENOME-WIDE ASSOCIATION; EGFR GENE; TYROSINE KINASE; COPY NUMBER; TRANSCRIPTION FACTOR; ACQUIRED-RESISTANCE; PLEURAL METASTASIS; SIGNALING PATHWAYS; TARGETED THERAPY; PROTEIN-BINDING;

D O I：

10.1155/2018/6192187

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recently, epidermal growth factor receptor (EGFR) was a key molecule in investigation of lung cancer, and it was a target for a new therapeutic strategy, based on molecular analyses. In this review, we have summarized some issues considering the role of EGFR in lung cancer, its coding gene, and its promoter gene polymorphisms (SNPs) -216G/T and -191C/A in non-small-cell lung cancer (NSCLC). The position of the SNPs indicates their significant role in EGFR regulation. The accumulation of knowledge regarding SNPs lately suggests their significant and important role in the onset of carcinogenesis, the prediction of the onset of metastases, the response to therapy with TKI inhibitors, and the onset of toxic effects of the applied therapy. Based on this, we suggest further studies of the relationship of clinical significance to SNPs in patients with lung tumors.

引用

页数：9

共 113 条

[1] [Anonymous], DATABASE SINGLE NUCL
[2] [Anonymous], 2016, COCHRANE DB SYST REV
[3] [Anonymous], TABLE PHARMACOGE NOM
[4] [Anonymous], THERAPEUTIC ADV MEDI
[5] Barber EA, 2016, AM J HEMATOL-ONCOL, V12, P4
[6] Bartholomew C, 2017, RESPIR MED CASE REP, V20, P137, DOI 10.1016/j.rmcr.2017.01.016
[7] The Association between Epidermal Growth Factor Receptor (EGFR) Gene Polymorphisms and Lung Cancer Risk
Bashir, Nabil A.
Ragab, Entesar S.
Khabour, Omar F.
Khassawneh, Basheer Y.
Alfaqih, Mahmoud A.
Momani, Jafar A.
[J]. BIOMOLECULES, 2018, 8 (03)
[8] Pathogenesis of lung cancer signalling pathways: roadmap for therapies
Brambilla, E.
Gazdar, A.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (06) : 1485 - 1497
[9] Mechanisms of egfr gene transcription modulation:: Relationship to cancer risk and therapy response
Brandt, Burkhard
Meyer-Staeckling, Soenke
Schmidt, Hartmut
Agelopoulos, Konstantin
Buerger, Horst
[J]. CLINICAL CANCER RESEARCH, 2006, 12 (24) : 7252 - 7260
[10] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer
Brugger, Wolfram
Triller, Nadja
Blasinska-Morawiec, Maria
Curescu, Stefan
Sakalauskas, Raimundas
Manikhas, Georgy Moiseevich
Mazieres, Julien
Whittom, Renaud
Ward, Carol
Mayne, Karen
Trunzer, Kerstin
Cappuzzo, Federico
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) : 4113 - 4120

← 1 2 3 4 5 6 7 8 9 10 →